摘要
目的评价阿托西班与利托君治疗早产的有效性及安全性。方法计算机检索相关数据库,全面收集阿托西班及利托君治疗早产的临床随机对照试验,对纳入文献进行Meta分析,使用Stata 12.0统计软件进行数据处理。结果 Meta分析结果显示两组治疗早产48h有效率(OR=1.24,95%CI:0.85～1.79,P=0.251)及7d有效率(OR=1.28,95%CI:0.98～1.67,P=0.715)比较差异均无统计学意义。两组新生儿平均分娩孕周(SMD=0.03,95%CI:-0.09～0.15,P=0.782)、平均出生体质量(SMD=-0.05,95%CI:-0.20～0.10,P=0.266)和不良反应发生率(OR=0.94,95%CI:0.77～1.16,P=0.063)比较差异均无统计学意义。阿托西班组母体呼吸困难、心动过速等不良反应发生率(OR=0.07,95%CI:0.04～0.13,P=0.000)及恶心、呕吐等不良反应发生率(OR=0.29,95%CI:0.21～0.39,P=0.000)均显著低于利托君组,差异均有统计学意义。结论阿托西班具有与利托君相似的保胎效果,不增加新生儿发病率及病死率,且母体不良反应发生率较低。
Objective To evaluate the effectiveness and safety of atosiban and ritodrine in the treatment of pretermbirth. Methods The studies of randomized trial on atosiban and ritodrine in treatment of preterm birth were searched andMeta-analysis was performed with Stata 12.0. Results The results showed the effectiveness of atosiban and ritodrine for pretermbirth at 48h（OR=1.24, 95%CI： 0.85-1.79, P=0.251） and at 7d（OR =1.28, 95%CI： 0.98-1.67, P=0.715）, there was no significantdifference between two groups. There were also no significant differences between the atosiban group and ritodrine group inaverage gestation age at birth（SMD=0.03, 95%CI ： -0.09-0.15, P=0.782） and the average weight at birth（SMD=-0.05,95%CI ： -0.20-0.10, P=0.266）. The incidence of dyspnea and tachycardia（OR=0.07, 95%CI： 0.04-0.13, P =0.000）, vomitingand headache（OR=0.29, 95%CI： 0.21-0.39, P =0.000） in the mother of atosiban group was significantly lower than those ofritodrine group. The incidence of adverse effects in the neonates was similar（OR=0.94, 95%CI： 0.77-1.16, P=0.063） in two groups.Conclusion Compared to ritodrine, atosiban can achieve the similar therapeutic effect in the treatment of preterm birth, withlower adverse effect in the mothers and without increasing adverse effects in the neonates.
作者
朱伟英
艾玲
ZHU Weiying;AI Ling(Department of Obstetrics,Jiaxing Maternal and Child Health Hospital,Jiaxing 314051,China)
出处
《浙江医学》
CAS
2018年第17期1937-1944,共8页
Zhejiang Medical Journal
关键词
阿托西班
利托君
早产
Atosiban
Ritodrine
Premature birth
